130 related articles for article (PubMed ID: 28120035)
21. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism.
Yang Y; Deng Y; Chen X; Zhang J; Chen Y; Li H; Wu Q; Yang Z; Zhang L; Liu B
Toxicol Lett; 2018 Oct; 295():88-98. PubMed ID: 29857117
[TBL] [Abstract][Full Text] [Related]
23. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
[TBL] [Abstract][Full Text] [Related]
24. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
25. Resistance to platinum-based chemotherapy in lung cancer cell lines.
Chen J; Emara N; Solomides C; Parekh H; Simpkins H
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1103-11. PubMed ID: 20953859
[TBL] [Abstract][Full Text] [Related]
26. Targeting GSTP1-1 induces JNK activation and leads to apoptosis in cisplatin-sensitive and -resistant human osteosarcoma cell lines.
Sau A; Filomeni G; Pezzola S; D'Aguanno S; Tregno FP; Urbani A; Serra M; Pasello M; Picci P; Federici G; Caccuri AM
Mol Biosyst; 2012 Apr; 8(4):994-1006. PubMed ID: 22068640
[TBL] [Abstract][Full Text] [Related]
27. Fenofibrate reduces cisplatin-induced apoptosis of renal proximal tubular cells via inhibition of JNK and p38 pathways.
Thongnuanjan P; Soodvilai S; Chatsudthipong V; Soodvilai S
J Toxicol Sci; 2016; 41(3):339-49. PubMed ID: 27193727
[TBL] [Abstract][Full Text] [Related]
28. Metformin enhances cisplatin cytotoxicity by suppressing signal transducer and activator of transcription-3 activity independently of the liver kinase B1-AMP-activated protein kinase pathway.
Lin CC; Yeh HH; Huang WL; Yan JJ; Lai WW; Su WP; Chen HH; Su WC
Am J Respir Cell Mol Biol; 2013 Aug; 49(2):241-50. PubMed ID: 23526220
[TBL] [Abstract][Full Text] [Related]
29. Cellular and biomolecular responses of human ovarian cancer cells to cytostatic dinuclear platinum(II) complexes.
Lin M; Wang X; Zhu J; Fan D; Zhang Y; Zhang J; Guo Z
Apoptosis; 2011 Mar; 16(3):288-300. PubMed ID: 21107699
[TBL] [Abstract][Full Text] [Related]
30. [Down-regulation of Nrf2 enhances the cytotoxicity of Oxaliplatin to H460 cells].
Xin A; Ren HY; Tang XW
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2010 Jan; 39(1):11-6. PubMed ID: 20175230
[TBL] [Abstract][Full Text] [Related]
31. ATF2 inhibits ani-tumor effects of BET inhibitor in a negative feedback manner by attenuating ferroptosis.
Wang L; Chen Y; Mi Y; Qiao J; Jin H; Li J; Lu Z; Wang Q; Zou Z
Biochem Biophys Res Commun; 2021 Jun; 558():216-223. PubMed ID: 33008584
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin.
Persons DL; Yazlovitskaya EM; Cui W; Pelling JC
Clin Cancer Res; 1999 May; 5(5):1007-14. PubMed ID: 10353733
[TBL] [Abstract][Full Text] [Related]
33. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance.
Cho JM; Manandhar S; Lee HR; Park HM; Kwak MK
Cancer Lett; 2008 Feb; 260(1-2):96-108. PubMed ID: 18036733
[TBL] [Abstract][Full Text] [Related]
34. Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells.
Nehmé A; Baskaran R; Nebel S; Fink D; Howell SB; Wang JY; Christen RD
Br J Cancer; 1999 Mar; 79(7-8):1104-10. PubMed ID: 10098743
[TBL] [Abstract][Full Text] [Related]
35. Superior cytotoxicity and DNA cross-link induction by oxaliplatin versus cisplatin at lower cellular uptake in colorectal cancer cell lines.
Virag P; Perde-Schrepler M; Fischer-Fodor E; Tatomir C; Dorneanu SA; Cernea VI; Irimie A
Anticancer Drugs; 2012 Nov; 23(10):1032-8. PubMed ID: 22614106
[TBL] [Abstract][Full Text] [Related]
36. The role of c-Jun N-terminal kinase, p38, and extracellular signal-regulated kinase in insulin-induced Thr69 and Thr71 phosphorylation of activating transcription factor 2.
Baan B; van Dam H; van der Zon GC; Maassen JA; Ouwens DM
Mol Endocrinol; 2006 Aug; 20(8):1786-95. PubMed ID: 16601071
[TBL] [Abstract][Full Text] [Related]
37. Activating transcription factor 2-derived peptides alter resistance of human tumor cell lines to ultraviolet irradiation and chemical treatment.
Bhoumik A; Ivanov V; Ronai Z
Clin Cancer Res; 2001 Feb; 7(2):331-42. PubMed ID: 11234888
[TBL] [Abstract][Full Text] [Related]
38. Nrf2 Activation as a Protective Feedback to Limit Cell Death in High Glucose-Exposed Cardiomyocytes.
Tsai CY; Wen SY; Cheng SY; Wang CH; Yang YC; Viswanadha VP; Huang CY; Kuo WW
J Cell Biochem; 2017 Jul; 118(7):1659-1669. PubMed ID: 27859591
[TBL] [Abstract][Full Text] [Related]
39. Pathophysiological roles of aldo-keto reductases (AKR1C1 and AKR1C3) in development of cisplatin resistance in human colon cancers.
Matsunaga T; Hojo A; Yamane Y; Endo S; El-Kabbani O; Hara A
Chem Biol Interact; 2013 Feb; 202(1-3):234-42. PubMed ID: 23165153
[TBL] [Abstract][Full Text] [Related]
40. Anticancer activity of Honokiol against lymphoid malignant cells via activation of ROS-JNK and attenuation of Nrf2 and NF-κB.
Gao DQ; Qian S; Ju T
J BUON; 2016; 21(3):673-9. PubMed ID: 27569089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
